

## What's in the price?

We maintain a BUY rating with a TP of Rs1,975 as we believe the fundamentals of the company continue to remain strong driven by robust growth visibility (factoring in revenue CAGR of 21.8% over FY21-24E) on back of completed capex. The stock is down 18% since our [last note](#) given the headwinds on the raw material front (key RMAT: phenol, PAP and PNCB). We believe this is a short-term aberration and are of a view that Valiant will be able to pass on the increase in the RM cost, albeit with a lag. Stock is currently trading at 9.2x EV/EBITDA Sept'23, which we believe is at a significant discount considering its legacy and leadership in Chlorophenol products, diverse chemistries, continued improvement in topline driven by capex and stabilisation of PAP plant.

- Margin pressure buoyed by soaring RMAT prices and lower operational efficiency:

- EBIDTA margins witnessed a contraction of 304bps QoQ (1093bps YoY) to 17.3% in Q2FY22 as RMAT prices such as phenol, PNCB and PAP are ~2x of that in 2020 on the back of increased freight cost coupled with issues relating to China (closure/relocation of plants, power issues and Covid-19 outbreaks). We believe that the margin pressure is short to medium term and Valiant should be able to pass through price increase with a lag.
- Operational efficiency is also impacted as revenue from PAP and Para Anisidine projects are meagre even though projects have commercialised.

Management has highlighted that some price pass through has transpired. However, raw material prices are still fluctuating and major benefits should be witnessed once prices stabilise.

- Sensitivity analysis in case of lower level of margins sustain: We've built a trough case where margin pressure continues through H2FY22-FY23E and rationalisation of RMAT prices is delayed. We assign a 15x EV/EBITDA (vs 18x in our base case) to Sept'23 EBIDTA indicating at a trough case TP of Rs1,420 on the lowered EBIDTA and a reduction in multiple.

- Robust growth visibility: The company witnessed strong sequential as well as YoY growth (65% YoY growth in H1FY22 vs H1FY21) as some of its completed capital investments have started contributing to revenues and we believe this revenue growth is sustainable driven by newer products.

- Para Anisidine: It was facing teething issues with PA manufacturing however the same is rectified and contribution is expected to increase from Q3FY22 onwards.
- OAP: manufacturing is expected to commercialise in Q4FY22 with significant ramp up in FY23.
- PAP: Valiant is currently producing PAP in small quantities (~100MT/m) and is working towards continuous PAP production as the same would result in reduction in overheads. Going forward, the management highlighted that they should be able to scale up manufacturing to the levels of ~300MT/m.
- Pharma intermediates: Valiant is in the midst of Rs500-600mn capex for pharma intermediates products with the intention to cater to domestic demand of pharma companies (mainly Aarti Group) and expects some contribution to flow Q4FY22 onwards, however, we believe significant contribution should be seen in FY23.

- Valuation and risks: Valiant is currently trading at 9.2x Sept'23 EV/EBIDTA which we believe is cheaper compared to peers considering its unique product portfolio and execution capabilities driving revenue growth. RMAT prices haven't cooled down significantly and we believe margin pressure should continue in the short to medium term. However, its long-term prospects continue to remain intact and we maintain our target multiple of 18x EV/EBITDA to arrive at TP of Rs1,975. At the trough case we value the company at 15x of Sept'23 EBIDTA to arrive at price of Rs1,420. **Key risks to thesis:** Delay in ramp-up in PAP production, commodity price inflation, promoter selling and an uptick in Chinese production.

Target Price	1,975	Key Data	
CMP	1,067	Bloomberg Code	VORG IN
Upside	85.1%	Curr Shares O/S (mn)	27.2
Price Performance (%)		Diluted Shares O/S(mn)	28.0
		Mkt Cap (Rsbm/USDmn)	29/389.4
		52 Wk H / L (Rs)	1991/1043
		1M	6M
		1Yr	
VORG IN (23.7%)	(37.8%)	(30.1%)	Daily Vol. (3M Avg.)
NIFTY (5.4%)	15.9%	36.4%	80455

Source: ACE Equity, Bloomberg, MNCL Research

## Shareholding pattern (%)

	Sep-21	Jun-21	Mar-21	Dec-20
Promoter	40.6	41.7	42.7	42.8
FII's	1.9	1.8	1.8	1.8
DII's	2.0	1.9	2.7	2.8
Others	55.5	54.6	52.8	52.6


Source: BSE

## Capacity expansion of products

Process	Capacity before expansion	Current Capacity
PAP	0 MT/m	1,000 MT/m
Para Anisidine	0 MT/m	150 MT/m
Ortho Anisidine	250-300 MT/m	400-500 MT/m
Ortho Amino Phenol	0 MT/m	80 MT/m

Source: MNCL Research

## Prices of key RM on the rise



Source: MNCL Research estimate, \*non-comparable due to acquisition

## Sensitivity Analysis (trough case)

	FY22E		FY23E		FY24E	
	Trough case	Base case	Trough case	Base case	Trough case	Base case
Rs mn	2,023	2,470	2,413	2,937	3,099	3,413
EBITDA	19%	23.2%	19.8%	24.1%	22.7%	25%
Ebitda margin	42	54	51	66	68	77

Source: MNCL Research

Srishti Jain  
srishti.jaini@mnclgroup.com

Y/E Mar (Rsmn)	Revenue	YoY (%)	EBITDA	EBITDA (%)	Adj PAT	YoY (%)	Adj EPS	RoE (%)	RoCE (%)	P/E (x)	EV/EBITDA (x)
FY19*	6,923	473.8%	1,798	26.0%	1,332	715.5%	54.8	85.9%	59.6%	21.2	7.4
FY20	6,749	(2.5%)	1,803	26.7%	1,239	(7.0)%	51.0	38.8%	28.7%	25.3	18.1
FY21	7,548	11.8%	2,052	27.2%	1,145	(7.6)%	42.2	25.7%	21.2%	25.3	14.9
FY22E	10,646	41.0%	2,470	23.2%	1,468	28.2%	54.1	26.1%	20.9%	19.7	12.4
FY23E	12,187	14.5%	2,937	24.1%	1,789	21.9%	65.9	25.7%	20.8%	16.2	10.1
FY24E	13,651	12.0%	3,413	25.0%	2,093	17.0%	77.1	24.6%	21.1%	13.8	8.4

Source: MNCL Research Estimates, \*non-comparable due to acquisition

# Financials (Consolidated)

## Exhibit 1: Income Statement

Y/E March (Rs mn)	FY16	FY17	FY18	FY19	FY20	FY21	FY22E	FY23E	FY24E
<b>Net Sales</b>	<b>521</b>	<b>734</b>	<b>1,206</b>	<b>6,923</b>	<b>6,749</b>	<b>7,548</b>	<b>10,646</b>	<b>12,187</b>	<b>13,651</b>
% growth	(11.8)	40.9	64.4	473.8	(2.5)	11.8	41.0	14.5	11.9
Raw Materials	251	426	635	4,264	3,931	4,187	6,462	7,227	7,986
% of sales	48.2	58.1	52.7	61.6	58.2	55.5	60.7	59.3	58.5
Personnel	23	33	48	185	228	294	373	427	491
% of sales	4.4	4.4	4.0	2.7	3.4	3.9	3.5	3.5	3.6
Other Expenses	89	91	259	677	788	1,016	1,341	1,597	1,761
% of sales	17.1	12.4	21.5	9.8	11.7	13.5	12.6	13.1	12.9
<b>EBITDA</b>	<b>158</b>	<b>184</b>	<b>264</b>	<b>1,798</b>	<b>1,803</b>	<b>2,052</b>	<b>2,470</b>	<b>2,937</b>	<b>3,413</b>
EBITDA Margin (%)	30.3	25.1	21.9	26.0	26.7	27.2	23.2	24.1	25.0
Depreciation	9	17	22	136	158	212	287	337	372
<b>EBIT</b>	<b>149</b>	<b>167</b>	<b>242</b>	<b>1,662</b>	<b>1,645</b>	<b>1,839</b>	<b>2,182</b>	<b>2,600</b>	<b>3,041</b>
Interest Expenses	5	3	5	37	23	50	83	98	90
<b>PBT From Operations</b>	<b>144</b>	<b>165</b>	<b>237</b>	<b>1,625</b>	<b>1,622</b>	<b>1,789</b>	<b>2,099</b>	<b>2,502</b>	<b>2,951</b>
Other Income	14	15	15	87	63	59	65	72	79
Exceptional items	-	-	-	-	-	-	-	-	-
<b>PBT after Exceptional</b>	<b>157</b>	<b>180</b>	<b>252</b>	<b>1,712</b>	<b>1,685</b>	<b>1,849</b>	<b>2,165</b>	<b>2,574</b>	<b>3,030</b>
Tax-Total	55	63	89	500	423	540	545	649	764
Effective Tax Rate (%)	35%	35%	35%	29%	25%	29%	25%	25%	25%
<b>PAT</b>	<b>103</b>	<b>117</b>	<b>163</b>	<b>1,213</b>	<b>1,262</b>	<b>1,309</b>	<b>1,619</b>	<b>1,925</b>	<b>2,266</b>
Minority Interest	-	-	-	-	23	164	151	137	173
Extraord. items -Adj.	-	-	-	120	-	-	-	-	-
<b>Reported PAT</b>	<b>103</b>	<b>117</b>	<b>163</b>	<b>1,332</b>	<b>1,239</b>	<b>1,145</b>	<b>1,498</b>	<b>1,789</b>	<b>2,093</b>

## Exhibit 2: Key Ratios

Y/E March	FY16	FY17	FY18	FY19	FY20	FY21	FY22E	FY23E	FY24E
<b>Growth ratios (%)</b>									
Net sales	(11.8)	40.9	64.4	473.8	(2.5)	11.8	41.0	14.5	12.0
EBITDA	41.2	16.8	43.3	580.9	0.3	13.8	20.4	18.9	16.2
Adjusted Net Profit	41.1	13.7	40.0	715.5	(7.0)	(7.6)	28.2	21.9	17.0
<b>Margin Ratio (%)</b>									
EBITDA Margin	30.3	25.1	21.9	26.0	26.7	27.2	23.2	24.1	25.0
EBIT Margin	28.5	22.8	20.1	24.0	24.4	24.4	20.5	21.3	22.3
PBT Margins	27.6	22.4	19.7	23.5	24.0	23.7	19.7	20.5	21.6
PAT Margin	19.7	15.9	13.5	19.2	18.4	15.2	13.8	14.7	15.3
<b>Return Ratio (%)</b>									
ROE	45.1	34.3	31.3	85.9	38.8	25.7	26.1	25.7	24.6
ROCE	41.9	31.9	29.6	59.6	28.7	21.4	20.9	20.8	21.1
ROIC	40.2	31.9	35.0	61.3	28.6	21.7	22.0	23.2	25.0
<b>Turnover Ratio days (days)</b>									
Gross Block Turnover Ratio	2.3	2.2	2.6	5.0	2.2	1.5	1.6	1.6	1.7
Inventory Period	17	47	21	25	24	35	31	30	29
Debtors Period	71	88	112	75	72	76	72	71	71
Creditors Period	24	63	76	39	48	52	49	48	48
Cash Conversion Cycle	65	72	58	61	48	59	54	53	52
<b>Solvency Ratio (x)</b>									
Debt-Equity	0.0	0.0	0.0	0.3	0.3	0.4	0.4	0.3	0.2
Net Debt-Equity	0.0	0.0	0.0	0.3	0.3	0.3	0.2	0.1	0.0
Current ratio	3.0	2.0	2.0	1.9	1.3	1.1	1.2	1.5	1.8
Interest coverage ratio	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gross Debt/EBITDA	0.1	0.0	0.0	0.4	0.7	0.9	0.9	0.7	0.5
<b>Dividend</b>									
Dividend per share	12.4	5.0	6.5	12.0	18.0	5.0	10.0	12.0	15.0
Dividend Payout (%)	70.9	25.1	23.3	24.5	24.1	11.9	18.5	18.2	19.5
Dividend Yield (%)	4.9	1.4	0.2	0.4	0.7	0.3	0.8	0.9	1.1
<b>Per share (Rs)</b>									
Basic EPS (reported)	17.5	19.9	27.9	54.8	51.0	42.2	54.1	65.9	77.1
Book Value	38.8	77.1	100.9	206.5	319.0	185.0	229.0	282.9	345.0
CEPS	19.1	22.8	31.6	120.9	115.0	50.0	64.6	78.3	90.8
Number of Shares (mn)	5.9	5.9	5.9	12.1	12.1	27.2	27.2	27.2	27.2
<b>Valuation</b>									
P/E	14.4	18.6	36.8	21.2	25.3	31.0	24.2	19.8	16.9
P/BV	6.5	4.8	10.1	5.0	8.1	7.1	5.7	4.6	3.8
EV/EBITDA	9.3	11.5	22.1	7.4	18.1	18.1	15.0	12.3	10.3
EV/Sales	2.8	2.9	4.8	1.9	4.8	4.9	3.5	3.0	2.6

Source: Company, MNCL Research Estimates

**Exhibit 3: Balance Sheet**

Y/E March (Rs mn)	FY16	FY17	FY18	FY19	FY20	FY21	FY22E	FY23E	FY24E
<b>SOURCES OF FUNDS</b>									
Capital	36	36	59	59	121	272	272	272	272
Reserves & Surplus	191	416	533	2,535	3,754	4,751	5,947	7,410	9,096
<b>Shareholders' Funds</b>	<b>228</b>	<b>452</b>	<b>592</b>	<b>2,594</b>	<b>3,876</b>	<b>5,023</b>	<b>6,219</b>	<b>7,682</b>	<b>9,368</b>
Minority Interest	-	-	-	116	131	63	214	351	524
<b>Total Loan Funds</b>	<b>10</b>	<b>6</b>	<b>6</b>	<b>826</b>	<b>1,381</b>	<b>1,991</b>	<b>2,307</b>	<b>2,067</b>	<b>1,689</b>
Deferred Tax Liabilities-Net	15	32	37	129	149	203	203	203	203
<b>Total Liabilities</b>	<b>252</b>	<b>490</b>	<b>635</b>	<b>3,665</b>	<b>5,537</b>	<b>7,280</b>	<b>8,943</b>	<b>10,302</b>	<b>11,784</b>
<b>APPLICATION OF FUNDS</b>									
Gross Block	223	431	494	2,293	3,717	6,263	7,103	7,873	8,651
Accumulated Depreciation	99	166	188	796	953	1,166	1,453	1,790	2,162
<b>Net Block</b>	<b>124</b>	<b>264</b>	<b>306</b>	<b>1,497</b>	<b>2,764</b>	<b>5,097</b>	<b>5,650</b>	<b>6,083</b>	<b>6,489</b>
CWIP	2	-	9	656	1,291	459	819	949	1,083
<b>Net Fixed Assets</b>	<b>126</b>	<b>264</b>	<b>315</b>	<b>2,153</b>	<b>4,055</b>	<b>5,556</b>	<b>6,468</b>	<b>7,032</b>	<b>7,572</b>
Investments	20	66	62	123	229	63	95	143	214
Inventories	25	94	71	479	449	722	904	1,002	1,085
Sundry debtors	102	177	369	1,414	1,326	1,568	2,100	2,371	2,655
Cash	11	50	116	36	127	310	865	1,454	2,193
Loans & Advances	124	33	29	277	68	65	99	140	180
Other assets	-	-	-	-	438	475	552	616	638
<b>Total Current Asset</b>	<b>262</b>	<b>354</b>	<b>584</b>	<b>2,207</b>	<b>2,407</b>	<b>3,139</b>	<b>4,520</b>	<b>5,582</b>	<b>6,751</b>
Trade Payables	34	126	250	743	879	1,072	1,429	1,603	1,795
Current Liabilities	2	3	12	24	238	345	612	735	823
Provisions	120	44	65	50	37	62	99	117	135
<b>Net Current Assets</b>	<b>107</b>	<b>182</b>	<b>257</b>	<b>1,389</b>	<b>1,254</b>	<b>1,660</b>	<b>2,380</b>	<b>3,128</b>	<b>3,998</b>
<b>Total Assets</b>	<b>252</b>	<b>512</b>	<b>635</b>	<b>3,665</b>	<b>5,537</b>	<b>7,280</b>	<b>8,943</b>	<b>10,302</b>	<b>11,784</b>

**Exhibit 4: Cash Flow**

Y/E March (Rs mn)	FY16	FY17	FY18	FY19	FY20	FY21	FY22E	FY23E	FY24E
<b>Operating profit before WC changes</b>	<b>168</b>	<b>196</b>	<b>273</b>	<b>1834</b>	<b>1,808</b>	<b>2,084</b>	<b>2470</b>	<b>2,937</b>	<b>3,413</b>
Net change in working capital	69	481	313	(542)	228	612	1,072	542	560
<b>Cash flow from operating activities (a)</b>	<b>178</b>	<b>95</b>	<b>178</b>	<b>760</b>	<b>1,613</b>	<b>1,129</b>	<b>1,567</b>	<b>2,094</b>	<b>2,474</b>
Capital Expenditure	18	40	64	890	2,050	1,713	1,200	900	912
FCF	163	56	117	(104)	(421)	(549)	429	1,268	1,630
<b>Cash flow from investing activities (b)</b>	<b>(15)</b>	<b>(37)</b>	<b>(62)</b>	<b>(882)</b>	<b>(1,836)</b>	<b>(1,564)</b>	<b>(1,107)</b>	<b>(840)</b>	<b>(860)</b>
<b>Cash flow from financing activities (c)</b>	<b>(160)</b>	<b>(42)</b>	<b>(50)</b>	<b>10</b>	<b>272</b>	<b>486</b>	<b>95</b>	<b>(664)</b>	<b>(875)</b>
<b>Net change in cash (a+b+c)</b>	<b>3</b>	<b>16</b>	<b>65</b>	<b>(112)</b>	<b>48</b>	<b>52</b>	<b>555</b>	<b>589</b>	<b>739</b>

Source: Company, MNCL Research Estimates

**Disclaimer:** Monarch Network Capital Limited (hereinafter MNCL), a publicly listed company, is engaged in services of retail broking, credits, portfolio management and marketing investment products including mutual funds, life & general insurance and as such prepares and shares research data and reports periodically with clients, investors, stake holders and general public in compliance with Securities and Exchange Board of India Act, 1992, Securities And Exchange Board Of India (Research Analysts) Regulations, 2014 and/or any other applicable directives, instructions or guidelines issued by the Regulators from time to time.

Research report is a written or electronic communication that includes research analysis, research recommendation or an opinion concerning securities or public offer, providing a basis for investment decisions. The views expressed therein are based solely on information available publicly/internal data/other reliable sources believed to be true. The information is provided merely as a complementary service and do not constitute an offer, solicitation for the purchase or sale of any financial instruments, inducement, promise, guarantee, warranty, or as an official confirmation of any transactions or contract of any kind.

Research data and reports published/ emailed/ text messaged via Short Messaging Services, Online Messengers, WhatsApp etc/transmitted through mobile application/s, including but not limited to FLIP™, Video Widget, telephony networks, print or electronic media and or those made available/uploaded on social networking sites (e.g. Facebook, Twitter, LinkedIn etc) by MNCL or those recommendation or offers or opinions concerning securities or public offer which are expressed as and during the course of "Public Appearance" are for informational purposes only. The reports are provided for assistance and are not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Though disseminated to clients simultaneously, not all clients may receive the reports at the same time. MNCL will not treat recipients as clients by virtue of their receiving this report.

The reports include projections, forecasts and other predictive statements which represent MNCL's assumptions and expectations in the light of currently available information. These projections and forecasts are based on industry trends, circumstances and factors which involve risks, variables and uncertainties. The actual performance of the companies represented in the report may vary from those projected. The projections and forecasts described in this reports should be evaluated keeping in mind the fact that these-

- are based on estimates and assumptions
- are subject to significant uncertainties and contingencies
- will vary from actual results and such variations may increase over a period of time
- are not scientifically proven to guarantee certain intended results
- are not published as a warranty and do not carry any evidentiary value.
- are not based on certain generally accepted accounting principles
- are not to be relied on in contractual, legal or tax advice.

Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice. Reports based on technical analysis is focused on studying charts of a stock's price movement and trading volume, as opposed to focusing on a company's fundamentals and as such, may not match with a report on a company's fundamentals.

Though we review the research reports for any untrue statements of material facts or any false or misleading information, , we do not represent that it is accurate or complete and it should not be relied on in connection with a commitment or contract whatsoever. Because of the possibility of human, technical or mechanical error by our sources of transmission of Reports/Data, we do not guarantee the accuracy, adequacy, completeness or availability of any information and are not to be held responsible for any errors or omissions or for the results obtained from the use of such information. MNCL and/or its Affiliates and its officers, directors and employees including the analysts/authors shall not be in any way responsible for any indirect, special or consequential damages that may arise to any person from any inadvertent error in the information contained in the reports nor do they take guarantee or assume liability for any omissions of the information contained therein. Information contained therein cannot be the basis for any claim, demand or cause of action. These data, reports and information do not constitute scientific publication and do not carry any evidentiary value whatsoever.

The reports are not for public distribution. Reproduction or dissemination, directly or indirectly, of research data and reports of MNCL in any form is prohibited except with the written permission of MNCL. Persons into whose possession the reports may come are required to observe these restrictions. Opinions expressed therein are our current opinion as of the date appearing on the report only. Data may be subject to update and correction without notice. While we endeavour to update on a reasonable basis the information discussed in the reports, there may be regulatory, compliance, or other reasons that prevent us from doing so.

The reports do not take into account the particular investment objectives, financial situations, risk profile or needs of individual clients. The user assumes the entire risk of any use made of this information. Each recipient of the reports should make such investigation as deemed necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in such reports (including the merits and risks involved).

Certain transactions - futures, options and other derivatives as well as non-investment grade securities - involve substantial risks and are not suitable for all investors. Investors may lose his/her entire investment under certain market conditions. Before acting on any advice or recommendation in this material, investors should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. The price and value of investments referred to in research reports and the income from them may fluctuate. Transaction costs may be significant in option strategies calling for multiple purchase and sales of options. Foreign currencies denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. Investors in securities such as ADRs, the value of which are influenced by foreign currencies effectively assume currency risk.

The recommendations in the reports are based on 12 month horizon, unless otherwise specified. The investment ratings are on absolute positive/negative return basis. It is possible that due to volatile price fluctuation in the near to medium term, there could be a temporary mismatch to rating. For reasons of valuations/return/lack of clarity/event we may revisit rating at appropriate time. The stocks always carry the risk of being upgraded to buy or downgraded to a hold, reduce or sell. The opinions expressed in the reports are subject to change but we have no obligation to tell our clients when our opinions or recommendations change. The reports are non-inclusive and do not consider all the information that the recipients may consider material to investments. The reports are issued by MNCL without any liability/undertaking/commitment on the part of itself or any of its entities.

Recipients of the research reports should assume that entities of MNCL may receive commission, brokerage, fees or other compensation from the company or companies that are the subject of the reports. We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of reports/data/material, may, from time to time have 'long' or 'short' positions in, act as principal in, and buy or sell the securities thereof of companies mentioned therein or be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as market maker in the financial instruments of the company/ies discussed therein or act as advisor or lender/borrower to such company/ies or have other potential conflicts of interests with respect to any recommendation and related information and opinions.

We further undertake that-

- No disciplinary action has been taken against the research analyst or MNCL by any authority in connection with their respective business activity.
- MNCL, Research analysts, persons reporting to research analysts and their relatives may have financial interests and material conflict of interest in the subject company.
- MNCL, Research analysts, persons reporting to research analysts and their relatives may have actual/beneficial ownership of 1% or more in the subject company's securities, at the month immediately preceding the date of publication of this research report.

Past performance is not a guide for future performance, future returns are not guaranteed and investors may suffer losses which may exceed their original capital.

The securities described herein may not be eligible for sale in all jurisdictions or to all categories of investors. The countries in which the companies mentioned in this report are organized may have restrictions on investments, voting rights or dealings in securities by nationals of other countries. Distributing/taking/sending/dispatching/transmitting this document in certain foreign jurisdictions may be restricted by law, and persons into whose possession this document comes should inform themselves about and observe any such restrictions. Failure to comply with this restriction may constitute a violation of any foreign jurisdiction laws.

The user should consult their own advisors to determine the merits and risks of investment and also read the Risk Disclosure Documents for Capital Markets and Derivative Segments as prescribed by Securities and Exchange Board of India before investing in the Indian Markets.

### Exhibit 5: Valiant Organic's Price Chart



Source: Bloomberg

Analyst holding in stock: **NO**

#### Key to MNCL Investment Rankings

Buy: Upside by >15%, Accumulate: Upside by 5% to 15%, Hold: Downside/Upside by -5% to +5%, Reduce: Downside by 5% to 15%, Sell: Downside by >15%

**Monarch Networth Capital Ltd. ([www.mnclgroup.com](http://www.mnclgroup.com))**

**Office:** - 9th Floor, Atlanta Centre, Sonawala Lane, Opp. Udyog Bhavan, Goregaon (E), Mumbai 400 063. Tel No.: 022 30641600